Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04927156
Other study ID # CIP-202002-BALT DEVICES
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 12, 2021
Est. completion date October 2041

Study information

Verified date February 2023
Source Balt Extrusion
Contact Clinical Affairs Department
Phone +33 1 39 89 46 41
Email Evidence@baltgroup.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices. This platform is purely exploratory, without hierarchical order of the objectives and associated outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date October 2041
Est. primary completion date June 2041
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Provision of a signed, written and dated informed consent or non-opposition (where applicable) Exclusion Criteria - Device(s) used in multiple procedures (two, or more, pathologies treated during the same procedure) - Contra-indications of each device as described in the instructions for use.

Study Design


Intervention

Device:
BALT medical devices
Includes, but is not limited to, the following: Access devices Aneurysm treatment devices Ischemic Stroke and peripheral occlusive diseases treatment devices Arterio-Venous Malformations/fistulas treatment devices

Locations

Country Name City State
France CHU Angers Angers
France CHU Grenoble Alpes La Tronche
France Hôpital Roger Salengro Lille
France Chu Tours Tours
Spain Hospital Clinico Universitario San Carlos Madrid
Spain Hospital: Fundacion Jimenez Diaz Madrid
Spain Hospital: Puerta de Hierro Madrid
Spain Unversitario Central de Asturias Oviedo
Spain Hospital Universitario Marqués de Valdecilla (HUMV) Santander
Spain Hospital Universitario Miguel Servet Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Balt Extrusion

Countries where clinical trial is conducted

France,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of occurrence of device-specific safety indicator(s). Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. From the procedure to 12 months post-procedure depending on the device family.
Primary Rate of devices achieving its intended use. Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. From the procedure to 12 months post-procedure depending on the device family.
Primary Rate of devices achieving its specific performance indicator(s). Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. From the procedure to 12 months post-procedure depending on the device family.
Primary Rate of devices in each category of the usability scale (Likert-type scale) for each usability indicator Qualitative measurement of usability for each usability indicator (i.e., good, well adapted, fairly adapted, bad). Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. From the procedure to 12 months post-procedure depending on the device family.
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3